KHN-921

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameKHN-921
Drug Alias NameKHN-921
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionMyosin-binding protein C, cardiac-type gene transference
TargetsMyosin-binding protein C, cardiac-type
Therapy Area/IndicationsCardiomyopathy, Hypertrophic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesChengdu Hongji Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesVanotech LtdChengdu Origen Biotechnology Co LtdChengdu Hongji Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCardiomyopathy, Hypertrophic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A